Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. cut its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 12.4% during the 2nd quarter, HoldingsChannel reports. The fund owned 12,665 shares of the company’s stock after selling 1,795 shares during the period. E Fund Management Co. Ltd.’s holdings in Intellia Therapeutics were worth $283,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in NTLA. Avidity Partners Management LP increased its stake in Intellia Therapeutics by 18.0% during the fourth quarter. Avidity Partners Management LP now owns 447,434 shares of the company’s stock valued at $13,642,000 after purchasing an additional 68,334 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Intellia Therapeutics by 2.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 700,228 shares of the company’s stock valued at $21,350,000 after purchasing an additional 18,987 shares during the last quarter. Opaleye Management Inc. bought a new stake in Intellia Therapeutics during the fourth quarter valued at $3,019,000. Vanguard Group Inc. increased its stake in Intellia Therapeutics by 1.9% during the fourth quarter. Vanguard Group Inc. now owns 8,347,449 shares of the company’s stock valued at $254,514,000 after purchasing an additional 155,579 shares during the last quarter. Finally, Comerica Bank increased its stake in Intellia Therapeutics by 853.6% during the first quarter. Comerica Bank now owns 37,105 shares of the company’s stock valued at $1,021,000 after purchasing an additional 33,214 shares during the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

Intellia Therapeutics Stock Down 0.1 %

Shares of NTLA opened at $22.52 on Thursday. The firm has a 50-day moving average price of $23.38 and a 200 day moving average price of $24.24. The firm has a market capitalization of $2.17 billion, a PE ratio of -4.20 and a beta of 1.77. Intellia Therapeutics, Inc. has a 52-week low of $19.21 and a 52-week high of $34.94.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.29). The business had revenue of $7.00 million for the quarter, compared to the consensus estimate of $19.68 million. During the same period last year, the firm earned ($1.40) earnings per share. The company’s revenue was down 48.5% compared to the same quarter last year. On average, equities analysts expect that Intellia Therapeutics, Inc. will post -5.19 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. JPMorgan Chase & Co. lowered their target price on shares of Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Truist Financial restated a “buy” rating and set a $120.00 price target on shares of Intellia Therapeutics in a research report on Monday, June 24th. Evercore ISI upgraded shares of Intellia Therapeutics to a “strong-buy” rating in a research report on Friday, August 9th. Cantor Fitzgerald restated an “overweight” rating and set a $65.00 price target on shares of Intellia Therapeutics in a research report on Monday, June 24th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $73.00 price target on shares of Intellia Therapeutics in a research report on Thursday, June 27th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $61.77.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.